Safety Information

Administration of exogenous surfactants, including INFASURF®, often rapidly improves oxygenation and lung compliance. Following INFASURF® administration, patients should be monitored so that oxygen and ventilatory support can be modified. During dosing with INFASURF®, the most common adverse reactions reported in clinical trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), and ETT reflux (21%). These events were generally transient, and not associated with serious complications. If any of these events occur, administration should be interrupted and the infant's condition stabilized.